UNICA IRIS Institutional Research Information System

LANZOLLA, Giulia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.185
AS - Asia 1.072
NA - Nord America 973
SA - Sud America 248
AF - Africa 38
OC - Oceania 31
Totale 4.547
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 1.940
US - Stati Uniti d'America 925
SG - Singapore 337
CN - Cina 322
BR - Brasile 170
VN - Vietnam 143
BD - Bangladesh 79
NL - Olanda 63
FI - Finlandia 50
HK - Hong Kong 44
AU - Australia 29
IN - India 28
FR - Francia 27
SE - Svezia 25
CA - Canada 24
ID - Indonesia 23
AR - Argentina 22
KR - Corea 20
MX - Messico 19
DE - Germania 17
PE - Perù 16
GB - Regno Unito 15
EC - Ecuador 12
CO - Colombia 11
PL - Polonia 11
TR - Turchia 9
DZ - Algeria 8
JO - Giordania 8
JP - Giappone 8
ZA - Sudafrica 8
AT - Austria 7
MA - Marocco 7
TH - Thailandia 7
CL - Cile 6
IE - Irlanda 6
MY - Malesia 6
IQ - Iraq 5
UA - Ucraina 5
JM - Giamaica 4
KE - Kenya 4
PT - Portogallo 4
SA - Arabia Saudita 4
VE - Venezuela 4
IR - Iran 3
PK - Pakistan 3
PY - Paraguay 3
RU - Federazione Russa 3
BO - Bolivia 2
EG - Egitto 2
ES - Italia 2
ET - Etiopia 2
KW - Kuwait 2
OM - Oman 2
PH - Filippine 2
TN - Tunisia 2
UY - Uruguay 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
SB - Salomone, isole 1
SD - Sudan 1
TW - Taiwan 1
Totale 4.547
Salva come PNG Salva come JPEG
Città #
Cagliari 1.734
Dallas 207
Singapore 207
San Jose 111
Ashburn 95
Council Bluffs 69
Beijing 60
Ho Chi Minh City 56
Hefei 51
Los Angeles 49
Chicago 41
Hanoi 37
Helsinki 37
Hong Kong 37
Amsterdam 23
São Paulo 23
Seoul 19
Lauterbourg 18
Heumen 16
Salt Lake City 16
Buffalo 15
New York 15
Guangzhou 14
Hengelo 14
Rome 14
Santa Clara 14
Orem 13
Redondo Beach 13
Lappeenranta 12
Melbourne 12
Tortolì 12
Mexico City 11
Montreal 10
Warsaw 10
Boardman 9
Rende 9
Xi'an 9
Brooklyn 8
Chennai 8
Frankfurt am Main 8
Rio de Janeiro 8
Amman 7
Brisbane 7
Da Nang 7
Jakarta 7
Lima 7
Maize 7
Miami 7
Selargius 7
Dublin 6
Sydney 6
Casalecchio di Reno 5
Elk Grove Village 5
Johannesburg 5
Manchester 5
Nuremberg 5
Phoenix 5
Shenzhen 5
Tampa 5
Algiers 4
Bangkok 4
Bogotá 4
Bologna 4
Brasília 4
Guayaquil 4
Hyderabad 4
Milan 4
Naples 4
Palermo 4
Porto 4
Queens 4
San Francisco 4
Santiago 4
Shenyang 4
Uta 4
Vienna 4
Agliana 3
Ankara 3
Atlanta 3
Baghdad 3
Bari 3
Belo Horizonte 3
Biên Hòa 3
Buenos Aires 3
Changzhou 3
Charlotte 3
Dhaka 3
Dulles 3
Genoa 3
Indianapolis 3
Jeddah 3
Lancaster 3
Logan 3
Louisa 3
Lviv 3
Nanjing 3
New Delhi 3
Pavia 3
Philadelphia 3
Poplar 3
Totale 3.392
Salva come PNG Salva come JPEG
Nome #
Graves disease: latest understanding of pathogenesis and treatment options 473
Oxidative phosphorylation in bone cells 428
Risk of Neck Hematoma Following Thyroidectomy in Patients Taking Direct Oral Anticoagulants: A Propensity Score Matching Analysis from Nine High-Volume European Centers (RAGNO Study) 249
Editorial: News in Graves’ orbitopathy: patients management and treatments 213
Detection of Central Compartment Lymph Node Metastasis of Thyroid Cancer: Usefulness of Intraoperative Thyroglobulin Measurement in Fine Needle Aspiration Washout with and Without Blue Dye Injection 172
Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III) 160
Graves’ Disease: Is It Time for Targeted Therapy? A Narrative Review 148
Long-term outcome of Graves’ orbitopathy following treatment with sirolimus 146
Osteoblastic erythropoietin is not required for bone mass accrual 144
HIF1 activation safeguards cortical bone formation against impaired oxidative phosphorylation 143
Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy 139
Ocular surface disease index in Graves’ orbitopathy: a cross-sectional study 130
Pharmacological inhibition of HIF2 protects against bone loss in an experimental model of estrogen deficiency 117
Sirolimus as a second-line treatment for Graves’ orbitopathy 115
Selenium in the Treatment of Graves’ Hyperthyroidism and Eye Disease 96
Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women 96
Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy 95
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-l1 blockade: Insights from four cases 88
Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves’ Orbitopathy: A Retrospective Cohort Study 84
Antioxidant Therapy in Graves’ Orbitopathy 79
IgG4 serum levels in Graves’ orbitopathy 78
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment 77
Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study 77
In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ orbitopathy 66
Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study 65
Absence of a relationship between vitamin D and Graves’ orbitopathy 58
Erythropoietin and skeletal cells crosstalks in physiology and disease 55
Insights into the Role of DNA Methylation and Gene Expression in Graves Orbitopathy 52
Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy 43
Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocols 42
Oxidative Stress in Graves Disease and Graves Orbitopathy 41
Androgens and Hypertension in Men and Women: a Unifying View 41
Immune checkpoint blockade Anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome 40
Statins in Graves Orbitopathy: A New Therapeutic Tool 39
null 39
Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis 35
Genetic Profiling of Orbital Fibroblasts from Patients with Graves' Orbitopathy 35
Graves’ disease and Graves’ orbitopathy following COVID-19 32
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy 32
Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk 31
Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ Disease: results of a pilot study 31
Statins: A New Hope on the Horizon of Graves Orbitopathy? 30
Occurrence of Graves’ hyperthyroidism and Graves’ orbitopathy after fine-needle aspiration biopsy of thyroid nodules 29
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study 29
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy 28
The Glu331del mutation in the CYP17A1 gene causes atypical congenital adrenal hyperplasia in a 46,XX female 24
Early familial non-medullary thyroid cancer: differences with late-onset and sporadic forms 22
Disappearance of Anti-Thyroid Autoantibodies following Thymectomy in Patients with Myasthenia Gravis 20
Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression 18
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial 18
null 16
Does preoperative administration of Lugol’s solution in patients undergoing thyroidectomy for Graves’ disease really improve surgical outcomes? A propensity score matching analysis from six high-volume centers (StELLinA study) 14
null 13
De-Escalating Thyroid Cancer Surgery: Insights and Unresolved Questions From the 2025 ATA Guidelines 13
null 12
null 12
null 10
null 10
null 8
Risk of Complications in Patients Undergoing Thyroidectomy for Graves' Disease (LUNA Study) 8
null 7
null 7
null 7
null 7
null 7
null 7
Totale 4.700
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.966
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.966
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.165 0 0 0 0 411 86 100 11 8 13 265 271
2025/20263.535 159 234 427 292 207 154 261 524 256 397 384 240
Totale 4.700